Browsing by Author "YAZIGI, R"

Now showing 1 - 4 of 4
  • No Thumbnail Available
    Item
    CYTOLOGIC DETECTION OF ENDOMETRIAL CARCINOMA BY THE ENDOCYTE TECHNIQUE
    (1983) YAZIGI, R; SANCHEZ, J; DUARTE, I; VERNI, J
    Patients (97) admitted for diagnostic curettage of peri- and postmenopausal bleeding underwent cytologic evaluation by the endocyte technique to test the accuracy of the method. Six patients with endometrial carcinoma were diagnosed by curettage and in 5 of them the cytologic specimens correctly agreed with histology; the other case was an inadequate sample for cytologic diagnosis. Hyperplastic endometrium was found in 14 cases by curettage; only 3 of them were detected by cytology. This cytologic technique proved to be satisfactory in diagnosing endometrial cancer but inadequate for detection of premalignant lesions.
  • No Thumbnail Available
    Item
    IFOSFAMIDE TREATMENT OF ADVANCED OVARIAN-CANCER
    (1984) YAZIGI, R; WILD, R; MADRID, J; ARRAZTOA, J
    To determine the efficacy of ifosfamide in the treatment of advanced ovarian malignancy, 20 patients with stages III and IV epithelial ovarian cancer were treated with this agent. Of these, 15 received the drug as primary chemotherapy. The response rate was 33%, with a median duration of remission of 13 mo. Five patients were treated with ifosfamide after failure with previous chemotherapy; no responses were seen in this group. Hematuria was observed in 2% of the treatment cycles with the use of the antidote mercapto-ethan-sulfonate acid. Though ifosfamide is an active drug in the treatment of patients with advanced ovarian cancer, it is not superior to traditional single alkylating agents.
  • No Thumbnail Available
    Item
    RESPONSE OF THE MATERNAL, FETAL, AND NEONATAL PITUITARY-THYROID AXIS TO THYROTROPIN-RELEASING-HORMONE
    (1986) MOYA, F; MENA, P; HEUSSER, F; FORADORI, A; PAIVA, E; YAZIGI, R; MICHAUD, P; GROSS, I
    Thyrotropin releasing hormone (TRH) readily crosses the placenta and stimulates the fetal pituitary. We studied the response of the maternal and fetal pituitary-thyroid axes to TRH and the influence of prenatal exposure to TRH on the physiological postnatal increase in thyrotropin (TSH) and triiodothyronine (T3) in the neonate. Twenty-six pregnant women received TRH (400 or 600 .mu.g) intravenous or saline (controls) either 2 or 12 h before elective cesarean section at term. Administration of 400 .mu.g of TRH resulted in significant elevations of maternal TSH (15.7 .+-. 2.9 versus 3.2 .+-. 0.4 .mu.U/ml, p < 0.01) and prolactin (416 .+-. 94 versus 223 .+-. 41 ng/ml, p < 0.05) 2 h later. Maternal T3 remained unchanged. A higher dose of TRH (600 .mu.g) produced comparable results. Maternal administration of TRH (400 .mu.g) 2 h before delivery resulted in significant increases in fetal TSH and T3 over controls (21.1 .+-. 3.7 versus 4.8 .+-. 1.0 .mu.U/ml, and 132 .+-. 12 versus 64 .+-. 9 ng/dl, p < 0.01, respectively). Cord blood hormone levels 12 hours after TRH administration were similar to controls. Higher doses of TRH did not produce further increases in fetal TSH or T3. Control and treated neonates demonstrated similar physiological postnatal increases in TSH and T3, suggesting that prior exposure to TRH did not blunt this response. These data suggest that maternal administration of TRH is an effective way of increasing fetal T3 levels, and that this treatment does not inhibit the postnatal surge is TSH and T3.
  • No Thumbnail Available
    Item
    SARCOMA COMPLICATING PREGNANCY
    (1986) YAZIGI, R; DRISCOLL, SG